NZ536633A - Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in women - Google Patents
Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in womenInfo
- Publication number
- NZ536633A NZ536633A NZ536633A NZ53663301A NZ536633A NZ 536633 A NZ536633 A NZ 536633A NZ 536633 A NZ536633 A NZ 536633A NZ 53663301 A NZ53663301 A NZ 53663301A NZ 536633 A NZ536633 A NZ 536633A
- Authority
- NZ
- New Zealand
- Prior art keywords
- testosterone
- kits
- compositions
- combinations
- methods
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 16
- 229960003604 testosterone Drugs 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 230000002950 deficient Effects 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001566 methyltestosterone Drugs 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
| US70375300A | 2000-11-01 | 2000-11-01 | |
| US29239801P | 2001-05-21 | 2001-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ536633A true NZ536633A (en) | 2006-03-31 |
Family
ID=27404127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ536633A NZ536633A (en) | 2000-08-30 | 2001-08-29 | Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in women |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1322336B1 (https=) |
| JP (1) | JP2004507511A (https=) |
| KR (1) | KR20030048021A (https=) |
| CN (1) | CN100349572C (https=) |
| AU (2) | AU2001285367B2 (https=) |
| BR (1) | BR0113649A (https=) |
| CA (1) | CA2419573C (https=) |
| DK (1) | DK1322336T3 (https=) |
| ES (1) | ES2423899T3 (https=) |
| IL (2) | IL154693A0 (https=) |
| MX (1) | MXPA03001859A (https=) |
| NO (1) | NO334991B1 (https=) |
| NZ (1) | NZ536633A (https=) |
| PL (1) | PL360992A1 (https=) |
| PT (1) | PT1322336E (https=) |
| WO (1) | WO2002017967A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| ATE355854T1 (de) | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| MXPA04008988A (es) * | 2002-03-15 | 2006-05-25 | Unimed Pharmaceuticals Inc | Composicion androgena farmaceutica y metodo para el tratamiento de la depresion. |
| BR0308584A (pt) * | 2002-03-15 | 2005-02-22 | Unimed Pharmaceuticals Inc | Composição farmacêutica androgênica e método para tratamento de depressão |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| AU2003240299B2 (en) * | 2002-06-25 | 2008-01-31 | Acrux Dds Pty. Ltd. | Metastable pharmaceutical compositions |
| KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
| AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
| US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| DK1670433T3 (da) | 2003-10-10 | 2012-03-12 | Ferring Bv | Transdermal farmaceutisk formulering til mindskelse af hudrester |
| US20070231373A1 (en) * | 2004-04-28 | 2007-10-04 | Hunter-Fleming Limited | Transdermal Steriod for Formulation |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| US20080058299A1 (en) * | 2005-04-12 | 2008-03-06 | Dudley Robert E | Method of treating or preventing bone deterioration or osteoporosis |
| EP1868590A4 (en) * | 2005-04-13 | 2012-08-29 | Unimed Pharmaceuticals Inc | PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN |
| WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| ZA200711040B (en) | 2005-06-03 | 2009-04-29 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| EP1896038B1 (en) * | 2005-06-03 | 2016-11-09 | Acrux DDS Pty Ltd | Method and composition for testosterone transdermal delivery |
| ES3012497T3 (en) | 2005-10-12 | 2025-04-09 | Besins Healthcare Lu Sarl | Improved testosterone gel and method of use |
| CA2646667C (en) | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| KR101528395B1 (ko) | 2009-12-23 | 2015-06-11 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
| PH12012500882A1 (en) | 2009-12-23 | 2013-01-07 | Colgate Palmolive Co | Oral care system, kit and method |
| KR101414966B1 (ko) | 2009-12-23 | 2014-07-04 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템, 키트 및 방법 |
| ES2496985T3 (es) | 2009-12-23 | 2014-09-22 | Colgate-Palmolive Company | Sistema de higiene buco-dental |
| US9642862B2 (en) | 2010-11-18 | 2017-05-09 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
| AU2019299538B2 (en) | 2018-07-05 | 2025-05-08 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| US12514862B2 (en) | 2020-02-05 | 2026-01-06 | Neurocrine UK Limited | Testosterone containing pharmaceutical composition |
| CN115754070B (zh) * | 2022-11-24 | 2025-11-25 | 深圳市第二人民医院(深圳市转化医学研究院) | 同时测定血液中总睾酮和游离睾酮含量的方法及试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| AU5855794A (en) * | 1993-01-19 | 1994-08-15 | Endorecherche Inc. | Therapeutic uses and delivery systems of dehydroepiandrosterone |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
| DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| KR20000070757A (ko) * | 1997-02-07 | 2000-11-25 | 에버트 챨스 디 | 테스토스테론 결핍증이 나타나는 여성에게 테스토스테론을 보충하는 방법 및 이에 이용되는 조성물 |
| US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| US6319913B1 (en) * | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
-
2001
- 2001-08-29 EP EP01964525.8A patent/EP1322336B1/en not_active Expired - Lifetime
- 2001-08-29 KR KR10-2003-7003111A patent/KR20030048021A/ko not_active Ceased
- 2001-08-29 AU AU2001285367A patent/AU2001285367B2/en not_active Expired
- 2001-08-29 PT PT1964525T patent/PT1322336E/pt unknown
- 2001-08-29 ES ES01964525T patent/ES2423899T3/es not_active Expired - Lifetime
- 2001-08-29 NZ NZ536633A patent/NZ536633A/xx not_active IP Right Cessation
- 2001-08-29 PL PL01360992A patent/PL360992A1/xx not_active Application Discontinuation
- 2001-08-29 JP JP2002522940A patent/JP2004507511A/ja active Pending
- 2001-08-29 CA CA002419573A patent/CA2419573C/en not_active Expired - Lifetime
- 2001-08-29 BR BR0113649-6A patent/BR0113649A/pt not_active Application Discontinuation
- 2001-08-29 MX MXPA03001859A patent/MXPA03001859A/es active IP Right Grant
- 2001-08-29 WO PCT/US2001/027199 patent/WO2002017967A1/en not_active Ceased
- 2001-08-29 AU AU8536701A patent/AU8536701A/xx active Pending
- 2001-08-29 DK DK01964525.8T patent/DK1322336T3/da active
- 2001-08-29 CN CNB018164331A patent/CN100349572C/zh not_active Expired - Lifetime
- 2001-08-29 IL IL15469301A patent/IL154693A0/xx unknown
-
2003
- 2003-02-28 NO NO20030954A patent/NO334991B1/no not_active IP Right Cessation
- 2003-02-28 IL IL154693A patent/IL154693A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2419573A1 (en) | 2002-03-07 |
| AU2001285367B2 (en) | 2006-05-18 |
| NO334991B1 (no) | 2014-08-18 |
| BR0113649A (pt) | 2004-07-20 |
| DK1322336T3 (da) | 2013-07-15 |
| NO20030954L (no) | 2003-04-28 |
| CN100349572C (zh) | 2007-11-21 |
| CA2419573C (en) | 2007-04-03 |
| HK1115537A1 (en) | 2008-12-05 |
| IL154693A0 (en) | 2003-09-17 |
| KR20030048021A (ko) | 2003-06-18 |
| EP1322336A1 (en) | 2003-07-02 |
| PT1322336E (pt) | 2013-08-05 |
| JP2004507511A (ja) | 2004-03-11 |
| HK1061804A1 (zh) | 2004-10-08 |
| ES2423899T3 (es) | 2013-09-25 |
| CN1466467A (zh) | 2004-01-07 |
| MXPA03001859A (es) | 2004-05-21 |
| IL154693A (en) | 2010-04-15 |
| EP1322336B1 (en) | 2013-07-03 |
| NO20030954D0 (no) | 2003-02-28 |
| AU8536701A (en) | 2002-03-13 |
| PL360992A1 (en) | 2004-09-20 |
| WO2002017967A1 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ536633A (en) | Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in women | |
| TR200300776T2 (tr) | Erkeklerde cinsel organ sertleşmemesinin tedavi edilmesi ve libidonun arttırılması için yöntem. | |
| NZ311304A (en) | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen | |
| ZA200203439B (en) | Novel tropical oestroprogestational compositions with systemic effect. | |
| PH30747A (en) | Combination therapy for the treatment of estrogen sensitive disease. | |
| NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
| MY106725A (en) | Method of treatment of androgen-related diseases. | |
| BRPI0408153A (pt) | formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo | |
| WO2006053172A3 (en) | The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases | |
| AU4728285A (en) | Pharmaceutical composition for combination therapy of hormonedependent cancers | |
| BRPI0516243B8 (pt) | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit | |
| BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
| Labrie et al. | Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7, 12-dimethylbenz (a) anthracene (DMBA)-induced mammary carcinoma in the rat | |
| WO1998005354A3 (en) | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors | |
| Cesur et al. | The use of antiandrogen flutamide in the treatment of hirsutism | |
| Förström | The influence of sex hormones on acne | |
| de Figueiredo Alves et al. | Comparison of gel and patch estradiol replacement in Brazil, a tropical country | |
| MXPA05003364A (es) | Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva. | |
| Aksel | Therapeutic approaches to androgen excess | |
| RU2003108852A (ru) | Способ повышения концентрации тестостерона и родственных стероидов у женщин | |
| Ekman | Total Androgen Blockade: The United States Experience | |
| HUP9902574A2 (hu) | Inkontinencia kezelésére alkalmas, nitrogén-monoxid-szintetáz szubsztrátokat és/vagy nitrogén-monoxid donorokat tartalmazó készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: LABORATOIRES BESINS INTERNATIONAL, FR Free format text: OLD OWNER(S): UNIMED PHARMACEUTICALS, INC. Owner name: UNIMED PHARMACEUTICALS, INC., US Free format text: OLD OWNER(S): UNIMED PHARMACEUTICALS, INC. |
|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: UNIMED PHARMACEUTICALS, LLC, NZ Effective date: 20140327 Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, NZ Effective date: 20140327 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 29 AUG 2021 BY RENEWALS TEAM Effective date: 20140802 |
|
| EXPY | Patent expired |